Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

Manisha Bhutani, MD, Monika House, RN, BA, Jiaxian He, MS, Shebli Atrash, David M Foureau, PhD, Barry Paul, MDMS, Reed Friend, MD, James T Symanowski, PhD, Sarah Norek, BSN, RN, Xhevahire Begic, MSPH, Donna Acampora, BSN, RN, Katherine K Farmer, BA, Carrie Ann Syfert, BSN, RN, Mauricio Pineda-Roman, MD, Peter Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-138485

Published: 2020

Journal Articles

High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2 , A Master Regulator of Mirna Maturation and B-Cell Development.

Yiming Zhou, Lijuan Chen, Bart Barlogie, MD, PhD, Owen Stephens, PhD, Xiaosong Wu, PhD, David Williams, PhD, Marie-astrid Cartron, PhD, Frits van Rhee, MD, PhD, Bijay Nair, MD, Sarah Waheed, MD, Mauricio Pineda-Roman, MD, PhD, Yazan Alsayed, MD, PhD, Elias Anaissie, MD, PhD, John D Shaughnessy, Jr.

Blood (2009) 114 (22): 1804.

https://doi.org/10.1182/blood.V114.22.1804.1804

Published: 2009

Journal Articles

Changes in the Expression of Proteasome Genes in Tumor Cells Following Short-Term Proteasome Inhibitor Therapy Predicts Survival in Multiple Myeloma Treated with Bortezomib-Containing Multi-Agent Chemotherapy

John D. Shaughnessy, Jr., PhD, Pingping Qu, MD, Ricky Edmondson, PhD, Damir Herman, PhD, Yiming Zhou, PhD, Erming Tian, Frits van Rhee, MD, PhD, Mauricio Pineda-Roman, MD, PhD, Yazan Alsayed, Elias Anaissie, Ya-wei Qiang, Joshua Epstein, PhD, Shmuel Yaccoby, PhD, David Williams, Fenghuang Zhan, PhD, Owen Stephens, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2008) 112 (11): 733.

https://doi.org/10.1182/blood.V112.11.733.733

Published: 2008

Journal Articles

Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5

Bart Barlogie, MD, PhD, Elias J. Anaissie, MD, John D. Shaughnessy, Jr., PhD, Frits van Rhee, MD, PhD, Mauricio Pineda-Roman, MD, Jeff Haessler, MD, Klaus A. Hollmig, MD, Yazan Alsayed, MD, Sarah Waheed, MD, Monica Graziutti, MD, Elias Kiwan, MD, John Crowley, PhD

Blood (2008) 112 (11): 162.

https://doi.org/10.1182/blood.V112.11.162.162

Published: 2008

Journal Articles

Integration of DNA Copy Number and Gene Expression Alterations Reveal Novel Insights into the Molecular Pathogenesis and Prognosis of Multiple Myeloma

Yiming Zhou, PhD, Bart Barlogie, MD, PhD, Damir Herman, PhD, Owen Stephens, PhD, Erming Tian, PhD, David Williams, PhD, Marie-astrid Cartron, PhD, Frits van Rhee, MD, PhD, Mauricio Pineda-Roman, MD, PhD, Yazan Alsayed, MD, PhD, Elias Anaissie, MD, PhD, Jeffrey Sawyer, Ph.D., John D. Shaughnessy, Jr., PhD

Blood (2008) 112 (11): 250.

https://doi.org/10.1182/blood.V112.11.250.250

Published: 2008

Journal Articles

MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2.

Ronald Walker, MD, John Shaughnessy, PhD, Jeffery Haessler, MS, Joshua Epstein, DSc, Jeffery Sawyer, PhD, Elias J. Anaissie, MD, Frits Van Rhee, MD PhD, Guido Tricot, MD PhD, Maurizio Zangari, MD, Mauricio Pineda-Roman, MD, Klaus Hollmig, MD, John Crowley, MD, Bart Barlogie, MD PhD

Blood (2006) 108 (11): 3515.

https://doi.org/10.1182/blood.V108.11.3515.3515

Published: 2006

Journal Articles

Rapidly Cycled Aggressive Lymphoma-Like Therapy (HD-DTPACE) for Salvage of Patients with Advanced Multiple Myeloma (MM).

Varant Arzoumanian, MD, Bart Barlogie, MD,PhD, Mauricio Pineda-Roman, MD, Klaus Hollmig, MD, Elias Anaissie, MD, Maurizio Zangari, MD, Somashekar Krishna, MD, Eilas Kiwan, MD, Guido Tricot, MD,PhD, Abid Mohiuddin, MD, Frits van Rhee, MD,PhD

Blood (2006) 108 (11): 3561.

https://doi.org/10.1182/blood.V108.11.3561.3561

Published: 2006

Journal Articles

Treatment Associated Venous Thromboembolism (VTE) and Survival in Multiple Myeloma Patients.

Maurizio Zangari, MD, Federica Cavallo, MD, Louis M. Fink, MD, Bart Barlogie, MD, PhD, Vanessa Bolejack, BS, Michael J. Burns, Elias Anaissie, MD, Klaus A. Hollmig, MD, Abid Mohiuddin, MD, Mauricio Pineda-Roman, MD, Guido J. Tricot, MD, PhD

Blood (2006) 108 (11): 3573.

https://doi.org/10.1182/blood.V108.11.3573.3573

Published: 2006

Journal Articles

Retrospective Analysis of Fractionated High-Dose Melphalan (F-MEL) and Bortezomib-Thalidomide-Dexamethasone (VTD) with Autotransplant (AT) Support for Advanced and Refractory Multiple Myeloma (AR-MM).

Mauricio Pineda-Roman, MD, Michelle H. Fox, MD, Klaus A. Hollmig, MD, Elias J. Anaissie, MD, Frits van Rhee, MD,PhD, Guido Tricot, MD,PhD, Maurizio Zangari, MD, Abid Mohiuddin, MD, Bart Barlogie, MD,PhD

Blood (2006) 108 (11): 3102.

https://doi.org/10.1182/blood.V108.11.3102.3102

Published: 2006

Journal Articles

Velcade (V)-Thalidomide (T)-Dexamethasone (D) for Advanced and Refractory Multiple Myeloma (MM): Long-Term Follow-Up of Phase I–II Trial UARK 2001-37: Superior Outcome in Patients with Normal Cytogenetics and No Prior T.

Maurizio Zangari, MD, Bart Barlogie, MD, PhD, Michael J. Burns, BS, BA, Vanessa Bolejack, MPH, Klaus A. Hollmig, MD, Frits van Rhee, MD, PhD, Mauricio Pineda-Roman, MD, Francesca Elice, MD, Guido J. Tricot, MD, PhD

Blood (2005) 106 (11): 2552.

https://doi.org/10.1182/blood.V106.11.2552.2552

Published: 2005

Journal Articles

Increased Stability of Bcl-2 mRNA in B-Cell Chronic Lymphocytic Leukemia (CLL).

Ebenezer A. Kio, MD, Mauricio Pineda-Roman, MD, Yoko Otake, MS, Robert K. Stuart, MD, Daniel J. Fernandes, PhD, DSc

Blood (2004) 104 (11): 4789.

https://doi.org/10.1182/blood.V104.11.4789.4789

Published: 2004

NARROW

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2 , A Master Regulator of Mirna Maturation and B-Cell Development.

Changes in the Expression of Proteasome Genes in Tumor Cells Following Short-Term Proteasome Inhibitor Therapy Predicts Survival in Multiple Myeloma Treated with Bortezomib-Containing Multi-Agent Chemotherapy

Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5

Integration of DNA Copy Number and Gene Expression Alterations Reveal Novel Insights into the Molecular Pathogenesis and Prognosis of Multiple Myeloma

MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2.

Rapidly Cycled Aggressive Lymphoma-Like Therapy (HD-DTPACE) for Salvage of Patients with Advanced Multiple Myeloma (MM).

Treatment Associated Venous Thromboembolism (VTE) and Survival in Multiple Myeloma Patients.

Retrospective Analysis of Fractionated High-Dose Melphalan (F-MEL) and Bortezomib-Thalidomide-Dexamethasone (VTD) with Autotransplant (AT) Support for Advanced and Refractory Multiple Myeloma (AR-MM).

Velcade (V)-Thalidomide (T)-Dexamethasone (D) for Advanced and Refractory Multiple Myeloma (MM): Long-Term Follow-Up of Phase I–II Trial UARK 2001-37: Superior Outcome in Patients with Normal Cytogenetics and No Prior T.

Increased Stability of Bcl-2 mRNA in B-Cell Chronic Lymphocytic Leukemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only